Elia Seguí

1.2k total citations
19 papers, 61 citations indexed

About

Elia Seguí is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Elia Seguí has authored 19 papers receiving a total of 61 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 5 papers in Cancer Research. Recurrent topics in Elia Seguí's work include Breast Cancer Treatment Studies (5 papers), Cancer Immunotherapy and Biomarkers (5 papers) and COVID-19 and healthcare impacts (5 papers). Elia Seguí is often cited by papers focused on Breast Cancer Treatment Studies (5 papers), Cancer Immunotherapy and Biomarkers (5 papers) and COVID-19 and healthcare impacts (5 papers). Elia Seguí collaborates with scholars based in Spain, Italy and France. Elia Seguí's co-authors include Aleix Prat, Francesco Schettini, Joan Padrosa, Javier Marco‐Hernández, Maggie C.U. Cheang, Richard Buus, Benedetta Conte, Zsolt Szíjgyártó, Giampaolo Tortora and Mitch Dowsett and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Elia Seguí

15 papers receiving 61 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Elia Seguí Spain 5 38 22 21 10 5 19 61
Marc Cucurull Spain 6 79 2.1× 12 0.5× 37 1.8× 9 0.9× 4 0.8× 17 110
Mohamed Elfagieh Libya 4 30 0.8× 19 0.9× 10 0.5× 6 0.6× 4 0.8× 9 64
Arrien A. Bertram United States 2 57 1.5× 21 1.0× 32 1.5× 20 2.0× 2 0.4× 3 78
J. Medioni France 5 45 1.2× 9 0.4× 36 1.7× 28 2.8× 4 0.8× 11 88
Jaseela Chiramel United Kingdom 4 55 1.4× 11 0.5× 28 1.3× 6 0.6× 2 0.4× 6 76
P. Damiano Italy 4 52 1.4× 20 0.9× 58 2.8× 10 1.0× 2 0.4× 5 94
Noah Theiss United States 3 25 0.7× 10 0.5× 23 1.1× 8 0.8× 2 0.4× 6 55
Larry Ka-Yue Chow Hong Kong 6 33 0.9× 28 1.3× 16 0.8× 10 1.0× 7 111
Daphné t’Kint de Roodenbeke Belgium 4 43 1.1× 15 0.7× 20 1.0× 14 1.4× 2 0.4× 7 60
Yock Ping Chow Malaysia 4 16 0.4× 18 0.8× 8 0.4× 6 0.6× 3 0.6× 9 55

Countries citing papers authored by Elia Seguí

Since Specialization
Citations

This map shows the geographic impact of Elia Seguí's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elia Seguí with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elia Seguí more than expected).

Fields of papers citing papers by Elia Seguí

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elia Seguí. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elia Seguí. The network helps show where Elia Seguí may publish in the future.

Co-authorship network of co-authors of Elia Seguí

This figure shows the co-authorship network connecting the top 25 collaborators of Elia Seguí. A scholar is included among the top collaborators of Elia Seguí based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elia Seguí. Elia Seguí is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Bravo, Raquel Gómez, et al.. (2025). The role of artificial intelligence integrating multi-omics in breast cancer. Revista de Senología y Patología Mamaria. 38(3). 100677–100677. 1 indexed citations
2.
Sanfeliu, Esther, Elia Seguí, Raquel Gómez Bravo, et al.. (2024). Abstract PO2-01-13: Clinico-Pathological and Molecular Characterization of Early Hormone Receptor-Positive Breast Cancer in Young Women. Cancer Research. 84(9_Supplement). PO2–1. 1 indexed citations
3.
Herreros, Marta García de, Joan Padrosa, Carme Font, et al.. (2024). Characterisation and Outcomes of Patients with Solid Organ Malignancies Admitted to the Intensive Care Unit: Mortality and Impact on Functional Status and Oncological Treatment. Diagnostics. 14(7). 730–730. 3 indexed citations
4.
Forget, Frédéric, Serafín Morales, Nuhad K. Ibrahim, et al.. (2024). AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in patients with HER2-neg/low metastatic breast cancer receiving paclitaxel, following an open-label dose optimization.. Journal of Clinical Oncology. 42(16_suppl). TPS1125–TPS1125. 1 indexed citations
5.
6.
Schettini, Francesco, Olga Martínez‐Sáez, Claudette Falato, et al.. (2023). Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis. ESMO Open. 8(3). 101214–101214. 8 indexed citations
7.
Seguí, Elia, et al.. (2022). Prognostic value of cutaneous reinnervation with GAP-43 in oxaliplatin-induced neuropathy. Journal of Neurology. 269(8). 4174–4184. 3 indexed citations
8.
Schettini, Francesco, Elia Seguí, Benedetta Conte, et al.. (2022). Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report. Frontiers in Oncology. 12. 1009352–1009352. 4 indexed citations
9.
Seguí, Elia, Édouard Auclin, David Casadevall, et al.. (2022). The FLARE score, circulating neutrophils, and association with COVID-19 outcomes in patients with solid tumors.. Journal of Clinical Oncology. 40(16_suppl). 2551–2551.
10.
Carbognin, Luisa, Francesco Schettini, Elia Seguí, et al.. (2022). Updated Neoadjuvant Treatment Landscape for Early Triple Negative Breast Cancer: Immunotherapy, Potential Predictive Biomarkers, and Novel Agents. Cancers. 14(17). 4064–4064. 12 indexed citations
11.
12.
Buus, Richard, Zsolt Szíjgyártó, Eugene F. Schuster, et al.. (2021). Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®. npj Breast Cancer. 7(1). 15–15. 9 indexed citations
13.
Teixidó, Cristina, Édouard Auclin, Roxana Reyes, et al.. (2021). 184P Association of tumor-associated neutrophils (TAN) with immunotherapy outcomes in patients in advanced non-small cell lung cancer. Annals of Oncology. 32. S1462–S1462.
14.
Martínez-Vila, Clara, Elia Seguí, Joan Padrosa, et al.. (2021). Encephalitis Associated With Immune Checkpoint Inhibitor Treatment in Patients With Melanoma. Journal of Immunotherapy. 44(5). 204–207. 3 indexed citations
15.
Seguí, Elia, Édouard Auclin, David Casadevall, et al.. (2020). 1714P Change of circulating pro-inflammatory markers between pre-COVID-19 condition and COVID-19 diagnosis predicts early death in cancer patients: The FLARE score. Annals of Oncology. 31. S1008–S1008. 1 indexed citations
16.
Seguí, Elia, Marta García de Herreros, Édouard Auclin, et al.. (2020). 1681P First results of the COCO study: COVID-19 outcomes in patients with cancer. Annals of Oncology. 31. S996–S996.
17.
Dettorre, Gino M, Nikolaos Diamantis, Angela Loizidou, et al.. (2020). 319O The systemic pro-inflammatory response identifies cancer patients with adverse outcomes from SARS-CoV-2 infection. Annals of Oncology. 31. S1366–S1366. 3 indexed citations
18.
Pinato, David J., Christopher C.T. Sng, Yien Ning Sophia Wong, et al.. (2020). 1679P Determinants of mortality from SARS-CoV-2 infection in European cancer patients. Annals of Oncology. 31. S995–S995.
19.
Seguí, Elia, et al.. (2008). [Postpartum hemolytic uremic syndrome: a rare entity and a treatment challenge].. PubMed. 28(1). 120–1. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marc Cucurull Breakdown of academic impact, for papers by Mohamed Elfagieh Breakdown of academic impact, for papers by Arrien A. Bertram Breakdown of academic impact, for papers by J. Medioni Breakdown of academic impact, for papers by Jaseela Chiramel Breakdown of academic impact, for papers by P. Damiano Breakdown of academic impact, for papers by Noah Theiss Breakdown of academic impact, for papers by Larry Ka-Yue Chow Breakdown of academic impact, for papers by Daphné t’Kint de Roodenbeke Breakdown of academic impact, for papers by Yock Ping Chow
Rankless by CCL
2026